已收盤 12-19 16:00:00 美东时间
-0.060
-2.65%
Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pioneering pattern-breaking approaches that treat root causes of obesity and type 2 diabetes ("T2D"), today
12-16 07:35
Gainers GT Biopharma (NASDAQ:GTBP) shares moved upwards by 6.6% to $0.65 durin...
12-06 05:05
今日重点评级关注:B. Riley证券:维持Seabridge Gold"买入"评级,目标价从50美元升至65美元;HC Wainwright & Co.:维持TRX Gold"买入"评级,目标价从1.2美元升至1.4美元
12-03 09:58
绩优股MongoDB大涨超22%,公司上调全年营收预测;Eventbrite飙升78.6%,拟被5亿美元收购并私有化>>
12-03 15:05
Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment1.5% mean weight change observed with Revita (n=17);
12-02 20:07
今日重点评级关注:Canaccord Genuity:维持Fractyl Health"买入"评级,目标价从6美元升至8美元;HC Wainwright & Co.:维持MediWound"买入"评级,目标价从31美元升至36美元
11-24 11:23
Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and raises the price target from $6 to $8.
11-22 02:30
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
Fractyl Health (NASDAQ:GUTS) will release its quarterly earnings report on Wedn...
11-12 01:12
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, Oct. 21, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Conventional small molecule approaches hav...
10-21 21:20